Clinical trial NCT04715230: Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
Official title: Meth-OD: A Phase 2a Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Methamphetamine Intoxication (Disorder)
Lead sponsor: InterveXion Therapeutics, LLC
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2021-01-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The hypothesis of this multisite Phase 2a study is that IXT-m200 will be well-tolerated in patients with acute mild to moderate METH toxicity. A randomized, open label design will be used in which one dose of IXT-m200 will be compared to treatment-as-usual (TAU). Approximately 40 participants will be enrolled in 4 cohorts. A dose escalation approach will be used so that progressively higher IXT-m200 doses will be evaluated in each cohort. In conjunction with safety monitoring, this design assures the opportunity to observe early safety findings before any participants are exposed to the next higher dose. The randomization ratio for IXT-m200 versus TAU is defined as 4:1 for each cohort so that the number of participants receiving TAU equals the number receiving each dose of IXT-m200 at the end of the study.

Agitation scales and vital signs will be recorded to track effect of the antibody treatment versus TAU over time on agitation associated with METH use. While in the emergency department (ED), detailed and pertinent medical and psychiatric histories, and physical exam will be obtained, along with laboratory assessments and ECGs. In the ED, participants will give blood samples for analysis of METH and IXT-m200 concentrations and followed for development of adverse events. Participants will be evaluated at 2 days and 4 weeks after discharge from the ED for adverse events and drug use history. Cohort escalation reviews will be performed by the Sponsor, Medical Monitor, and Data and Safety Monitoring Board (DSMB) between cohorts and the next group will not start until after completion of this review.


Eligibility criteria: Inclusion Criteria:

1. Be aged 18 to 45 years, inclusive;
2. Present to the ED with METH toxicity as defined in protocol;
3. Have a PANSS-EC score of 14-28, inclusive;
4. Have or agrees to have an intravenous (IV) line placed;
5. Give a history of METH use in the past 24 hours, with participant or observer attribution of symptoms to METH, or have a positive METH drug screen;
6. Be accompanied or readily represented by a legally authorized representative (surrogate) who can consent to participation on behalf of the participant; and
7. Assent to participation in the study.

Exclusion Criteria:

1. Present with concomitant opioid overdose requiring ventilatory support;
2. Be self-reported to be pregnant or lactating;
3. Be considered to have significant concomitant medical illness or trauma, or symptoms of severe METH toxicity including

   1. sepsis or febrile illness;
   2. myocardial infarction, cardiac decompensation or arrhythmias including tachycardia that is not sinus; severe hypertension (\>180/110 mmHg); inadequately treated hypertension on chronic medication; history of vasculitis
   3. coma, stroke or severe head injury; new or ongoing seizure activity
   4. acute pulmonary decompensation or severe chronic obstructive pulmonary disease;
   5. any hepatic impairment and/or acute hepatitis or renal impairment due to concomitant medical illness; or
   6. current, or history of, neuroleptic malignant syndrome
4. Be considered to be at imminent risk of suicide or have disqualifying answers to the following two questions. Disqualifying answers would be 1b2 or 2b. 1. In the past 30 days, have you considered killing yourself? a) No; b) Yes - if Yes, how often? b1) Not often (twice or less), b2) Somewhat often (more than twice). 2. In the past year, have you attempted to kill yourself? a) No; b) Yes;
5. Be considered to be at imminent risk of injury or danger to self, others or property;
6. Have a history of severe allergy (rash, hives, breathing difficulty, etc.), known hypersensitivity or infusion reaction to any antibody medications, lorazepam or haloperidol; or
7. Be judged by the treating ED physician, investigator, or Sponsor (or designee) to be inappropriate for the study, including people whom the investigator determines cannot reasonably be consulted for assent to participation.

Primary outcomes:
measure: Number of Patients With Treatment-related Adverse Events (AEs) as Measured by Vital Signs
timeFrame: 28 days
measure: Number of Patients With Treatment-related AEs as Measured by Physical Examinations
timeFrame: 28 days
measure: Number of Patients With Treatment-related AEs as Measured by Clinical Laboratory Testing
timeFrame: 3 days
measure: Number of Patients With Treatment-related AEs as Measured by Electrocardiogram
timeFrame: 4 hours
Secondary outcomes:
measure: Time Course and Degree of Normalization of Agitation
timeFrame: Baseline and hours 0.5, 1, 2, 3, 4, and 8 post-dose or until discharge.
measure: Number of Participants at Certain Degrees of Normalization of Blood Pressure Over Time
timeFrame: Baseline and hours 0.5, 1, 2, 3, 4, and 8 post-dose or until discharge.
measure: Number of Participants at Certain Degrees of Normalization of Heart Rate Over Time
timeFrame: Baseline and hours 0.5, 1, 2, 3, 4, and 8 post-dose or until discharge.
measure: Time Course and Degree of Normalization of Temperature
timeFrame: Baseline and hours 0.5, 1, 2, 3, 4, and 8 post-dose or until discharge.
measure: Number of Participants Requiring Rescue Medications for Psychiatric or Cardiovascular Manifestations of METH Toxicity
timeFrame: 8 hours
Other outcomes:
measure: Length of Patient Stay in the ED
timeFrame: Start of treatment until discharge
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
city: Albuquerque
country: United States
facility: University of New Mexico Hospital
state: New Mexico
city: Everett
country: United States
facility: Providence Regional Medical Center Everett
state: Washington
city: Spokane
country: United States
facility: Sacred Heart Medical Center
state: Washington
Study officials:
affiliation: InterveXion Therapeutics
name: Chief Medical Officer
role: STUDY_DIRECTOR
References: